SCHEDULE: FMR LLC Reports 11.4% Stake in Vaxcyte Inc.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 11.4% of Vaxcyte Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Vaxcyte Inc. common stock.
• As of March 31, 2026, the aggregate amount beneficially owned is 16,451,061.32 shares.
• This represents 11.4% of the class of securities.
• FMR LLC holds sole voting power for 16,045,941.89 shares and sole dispositive power for 16,451,061.32 shares.
• Abigail P. Johnson has sole dispositive power for 16,451,061.32 shares.
• The filing is made under Rule 13d-1(b), classifying FMR LLC as an investment adviser.
• Several entities, including FIAM LLC, Fidelity Institutional Asset Management Trust Company BK, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, are identified as relevant entities within the FMR Reporters group.
• Abigail P. Johnson is identified as a Director, Chairman, and CEO of FMR LLC, with members of the Johnson family being predominant owners of FMR LLC's voting shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates substantial institutional interest from a reputable asset manager, but provides no new operational or financial information about Vaxcyte Inc. itself.

Positives

• Significant beneficial ownership of 11.4% by FMR LLC and Abigail P. Johnson indicates substantial investor confidence or strategic interest in Vaxcyte Inc.
• The filing is made under Rule 13d-1(b), suggesting FMR LLC is acting as an investment adviser, which is a standard and regulated capacity.
• The clear reporting of beneficial ownership and voting/dispositive power provides transparency to the market regarding a major shareholder's holdings.

Negatives

• The filing does not contain specific financial performance data for Vaxcyte Inc., only ownership information.
• No details are provided regarding the specific reasons for this level of investment or any strategic plans involving Vaxcyte Inc.

Risks

• The filing does not explicitly mention any risks associated with Vaxcyte Inc. or the investment itself.
• Potential risks for Vaxcyte Inc. could include those typical for biotechnology companies, such as clinical trial failures, regulatory hurdles, and competition, though these are not detailed in this filing.

Future Outlook

This filing is primarily an ownership disclosure and does not contain forward-looking statements or guidance regarding Vaxcyte Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in this Schedule 13G filing by FMR LLC, is common in the biotechnology sector. Such filings often signal sustained investor interest and can influence market perception of a company's stability and growth potential.

Stakeholder Impact

• Shareholders: Increased transparency regarding a major institutional holder's stake, potentially influencing market perception and trading activity.
• Management of Vaxcyte Inc.: Confirmation of significant institutional support, which can be viewed positively.
• Competitors: The filing itself does not directly impact competitors but highlights Vaxcyte Inc. as a company attracting significant institutional capital.

Next Steps

• Continued monitoring of Vaxcyte Inc.'s operational and financial performance.
• Observation of any future filings or announcements from FMR LLC or Abigail P. Johnson regarding their stake in Vaxcyte Inc.

Key Dates

Keywords

Vaxcyte Inc., Schedule 13G, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Biotechnology, Healthcare